



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/644,775
Filing Date	August 21, 2003
First Named Inventor	TENNENBAUM
Art Unit	1615
Examiner Name	

Sheet	1	of	3	Attorney Docket Number	26306
-------	---	----	---	------------------------	-------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/MA/ ↓	1	US-5,145,679	08-8-1992	Hinson	
	2	US-4,833,257	05-23-1989	Pettit et al.	
	3	US-5,591,709	07-7-1997	Lindenbaum	
	4	US-5,461,030	10-24-1995	Lindenbaum	
	5	US-2002/0119914	08-29-2002	Zhu et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
/MA/ ↓	6	PCT WO 96/23522	08-8-1996	Zimmet		
	7	EP 0679402	02-2-1995	Yoshida et al.		
	8	EP 0561330	09-22-1993	Liedtke		
	9	PCT WO 99/35283	07-15-1999	Mercurio et al.		
	10	PCT WO 92/18147	10-29-1992	Owen et al.		
	11	PCT WO 99/18920	04-22-1999	Zhu		
	12	PCT WO 85/05036	11-21-1985	Weber et al.		
	13	PCT WO 96/09810	04-4-1996	Gilchrest et al.		
	14	PCT WO 96/20724	07-11-1996	Hartman et al.		
	15	WO 01/76650	10-18-2001	Newell et al.		

Examiner Signature	/Marianne Allen/	Date Considered	05/30/2007
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/644,775
				Filing Date	August 21, 2003
				First Named Inventor	TENNENBAUM
				Group Art Unit	1615
				Examiner Name	
Sheet	2	Of	3	Attorney Docket Number	26306
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/MA/	16	Ferber et al. "Pancreatic and Duodenal Homeobox Gene 1 Induces Expression of Insulin Genes in Liver and Ameliorates Streptozotocin-Induced Hyperglycemia", Nature Medicine, 6(5): 568-572, 2000.			
	17	Hengge et al. "Epidermis as Target for In Vivo Gene-Therapy", Journal of Investigative Dermatology, 105(3): 448, 1995. Abstract.			
	18	Setoguchi et al. "Ex Vivo and In Vivo Gene Transfer to the Skin Using Replication-Deficient Recombinant Adenovirus Vectors", The Journal of Investigative Dermatology, 102(4): 415-421, 1994.			
	19	Ohba et al. "Induction of Differentiation in Normal Human Keratinocytes by Adenovirus-Mediated Introduction of the Eta and Delta Isoforms of Protein Kinase C", Molecular and Cellular Biology, 18(9): 5199-5207, 1998.			
	20	Macfarlane et al. "Glucose Stimulates Translocation of the Homeodomain of Transcription Factor PDX1 From the Cytoplasm to the Nucleus of Pancreatic Bet-Cells", J. Biol. Chem., 274(2): 1001-1016, 1999.			
	21	Lindenbaum et al. "Serum-Free Cell Culture Medium Induces Acceleration of wound Healing in Guenia-Pigs", Burns, 21(2): 110-115, 1995.			
	22	Braiman et al. "Protein Kinase C-Delta Mediates Insulin-Induced Glucose Transport in Primary Cultures of Rat Skeletal Muscle", Molecular Endocrinology, 13(12): 2002-2012, 1999.			
	23	Jeschke et al. "Effect of Multiple Gene Transfers of Insulinlike Growth Factor I Complementary DNA Gene Constucts in Rats After Thermal Injury", Archives of Surgery, 134(10): 1137-1141, 1999.			
	24	Braiman et al. "Tyrosine Phosphorylation of Specific Protein Kinase C Isoenzymes Participates in Insulin Stimulation of Glucose Transport in Primary Cultures of Rat Skeletal Muscle", Diabetes, 48(10): 1922-1929, 1999.			
	25	Bitar et al. "Insulin and Glucocorticoid-Dependent Suppression of the IGF-I System I Diabetic Wounds", Surgery, 127(6): 687-695, 2000.			
	26	Pittelkow et al. "Serum-Free Culture of Normal Human Melanocytes: Growth Kinetics and Growth Factor Requirements", Journal of Cellular Physiology, 140(3): 565-576, 1989.			
	27	Andre et al. "Protein Kinases C-Gamma and -Delta Are Involved in Insulin - Like Growth Factor I- Induced Migration of Colonic Epithelial Cells", Gastroenterology, 116(1): 64-77, 1999.			
	28	Shen et al. "PKC Delta Activation: A Divergence Point in the Signaling of Insulin and IGF-1-Induced Proliferation of Skin Keratinocytes", Diabetes, 50(2): 255-264, 2001.			
	29	Spravchikov et al. "Glucose Effects on Skin Keratinocytes: Implications for Diabetes Skin Complications", Diabetes, 50(7): 1627-1635, 2001.			
	30	Jeschke et al. "IGF-I Gene Transfer in Thermally Injured Rats", Gene Therapy, 6(6): 1015-1020, 1999.			
Examiner Signature	/Marianne Allen/			Date	05/30/2007
				Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/644,775
				Filing Date	August 21, 2003
				First Named Inventor	TENNENBAUM
				Group Art Unit	1615
				Examiner Name	
Sheet	3	Of	3	Attorney Docket Number 26306	
/MA/ ↓ ↓	31	Taran et al. "Improved Vitality of Experimental Random Dorsal Skin Flaps in Rats Treated With Enriched Cell Culture Medium", Plastic and Reconstructive Surgery, 104(1): 148-151, 1999.			
	32	Spravchikov et al. "The Interactive Effects of Hyperglycemia, Insulin and IGF-1 in Murine Skin Cells: An Ir-Null Mouse Model", Diabetologia, 43(Suppl.1): A 176, 2000.			
	33	Wertheimer et al. "The Regulation of Skin Proliferation and Differentiation in the IR Null Mouse: Implications for Skin Complications of Diabetes", Endocrinology, 142(3): 1234-1241, Mar 2001.			
Examiner	/Marianne Allen/			Date	05/30/2007
Signature				Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.